The iLite^® IL-23 Assay Ready Cells can be used for the quantification of IL-23 or p40 inhibitor activity, or the neutralizing antibody response against such inhibitors in human serum. 

Application notes for the following assays are available:

• Quantification of IL-23 inhibitor activity using iLite^® IL-23 Assay Ready Cells (E-206-GB)
• Determination of neutralizing antibodies against IL-23 inhibitors using iLite^® IL-23 Assay Ready Cells

Interleukin 23 (IL-23) is a heterodimeric pro-inflammatory cytokine that shares traits with IL-12. Both cytokines contain the p40 subunit which binds to the receptor chain IL-12Rβ1. However, the two cytokines exert distinct non-redundant biological functions. IL-23 has been implicated as an inflammation mediator in several autoimmune diseases, and has also been found to promote tumour growth. Therapeutic agents targeting both IL-12 and IL-23 cytokines are currently used to treat psoriasis and psoriatic arthritis, and related agents are in clinical testing for a variety of inflammatory disorders.

>250 µL of Assay Ready Cells suspended in RPMI 1640 medium with 20% heat inactivated fetal bovine serum (FBS) and 10% dimethyl sulfoxide (DMSO).